x
Filter:
Filters applied
- Melanoma
- TCGARemove TCGA filter
- microRNARemove microRNA filter
Keyword
- miRNA2
- The Cancer Genome Atlas2
- AJCC1
- American Joint Committee on Cancer1
- leave-one-out cross-validation1
- LOOCV1
- microphthalmia-associated transcription factor1
- miR1
- MITF1
- NEDD91
- neural precursor cell expressed developmentally down-regulated protein 91
- NHEM1
- normal human epidermal melanocytes1
- TCF41
- transcription factor 41
Melanoma
2 Results
- Original Article Melanocytes/MelanomaOpen Archive
Regulation of Melanoma Progression through the TCF4/miR-125b/NEDD9 Cascade
Journal of Investigative DermatologyVol. 136Issue 6p1229–1237Published online: March 8, 2016- Florian Rambow
- Audrey Bechadergue
- Flavie Luciani
- Gwendoline Gros
- Melanie Domingues
- Jacky Bonaventure
- and others
Cited in Scopus: 20Melanoma progression from a primary lesion to a distant metastasis is a complex process associated with genetic alterations, epigenetic modifications, and phenotypic switches. Elucidation of these phenomena may indicate how to interfere with this fatal disease. The role of microRNAs as key negative regulators of gene expression, controlling all cellular processes including cell migration and invasion, is now being recognized. Here, we used in silico analysis of microRNA expression profiles of primary and metastatic melanomas and functional experiments to show that microRNA-125b (miR-125b) is a determinant candidate of melanoma progression: (i) miR-125b is more strongly expressed in aggressive metastatic than primary melanomas, (ii) there is an inverse correlation between the amount of miR-125b and overall patient survival, (iii) invasion/migration potentials in vitro are inversely correlated with the amount of miR-125b in a series of human melanoma cell lines, and (iv) inhibition of miR-125b reduces migratory and invasive potentials without affecting cell proliferation in vitro. - Original Article Melanocytes/MelanomaOpen Archive
Identification, Review, and Systematic Cross-Validation of microRNA Prognostic Signatures in Metastatic Melanoma
Journal of Investigative DermatologyVol. 136Issue 1p245–254Published in issue: January, 2016- Kaushala Jayawardana
- Sarah-Jane Schramm
- Varsha Tembe
- Samuel Mueller
- John F. Thompson
- Richard A. Scolyer
- and others
Cited in Scopus: 58In metastatic melanoma, it is vital to identify and validate biomarkers of prognosis. Previous studies have systematically evaluated protein biomarkers or mRNA-based expression signatures. No such analyses have been applied to microRNA (miRNA)-based prognostic signatures. As a first step, we identified two prognostic miRNA signatures from publicly available data sets (Gene Expression Omnibus/The Cancer Genome Atlas) of global miRNA expression profiling information. A 12-miRNA signature predicted longer survival after surgery for resection of American Joint Committee on Cancer stage III disease (>4 years, no sign of relapse) and outperformed American Joint Committee on Cancer standard-of-care prognostic markers in leave-one-out cross-validation analysis (error rates 34% and 38%, respectively).